de Vlam Kurt, Bruhwyler Jacques, Boone Caroline
Division of Rheumatology, Department of Musculoskeletal Sciences, University Hospitals Leuven, Leuven, Belgium.
Medical Department, ECSOR sa/nv, Temploux, Belgium.
Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1094-1097. Epub 2016 Aug 31.
To determine if patients with psoriatic arthritis (PsA) who achieved remission within 6 months with etanercept (ETN) treatment (with or without methotrexate) were able to maintain remission over 66 months. Monotherapy status over the study duration was also monitored.
This was a post hoc analysis of PROVE (NCT00938015), a multicentre, observational study into the long-term adherence of ETN performed in rheumatology clinics in Belgium. To be included in PROVE, patients had active PsA and were either already receiving ETN treatment or had recently been prescribed it. Patients who achieved remission (defined as zero joints with synovitis) after 6 months of ETN treatment were monitored for maintenance of remission at each subsequent visit. In addition, patients on ETN monotherapy at Month 6 were observed.
303 patients participated and 156 (51.5%) patients completed 66 months of ETN treatment. The mean (standard deviation [SD]) disease duration was 7.5 (7.4) years and the majority had polyarticular-type PsA (87.1%). Overall, 142 patients achieved remission after 6 months of ETN treatment. Among the 83 patients who were in remission at Month 6 and remained in the study until the end, 72 (86.7%) were still in remission at Month 66. After 6 months, 66 patients were receiving ETN monotherapy and the majority continued with it until Month 66 (n=22/26; 84.6%).
Within this patient population, remission was achieved quickly and was sustained in the long-term. Of those patients who were receiving monotherapy, most continued with this treatment strategy for the duration of the study.
确定使用依那西普（ETN）治疗（联合或不联合甲氨蝶呤）6个月内达到缓解的银屑病关节炎（PsA）患者能否在66个月内维持缓解状态。同时监测整个研究期间的单药治疗情况。
这是一项对PROVE（NCT00938015）研究的事后分析，PROVE是一项在比利时风湿病诊所进行的关于ETN长期依从性的多中心观察性研究。纳入PROVE研究的患者患有活动性PsA，且已在接受ETN治疗或最近刚被处方使用ETN。ETN治疗6个月后达到缓解（定义为无滑膜炎关节）的患者在随后的每次随访中监测缓解状态的维持情况。此外，观察在第6个月接受ETN单药治疗的患者。
303例患者参与研究，156例（51.5%）患者完成了66个月的ETN治疗。平均（标准差[SD]）病程为7.5（7.4）年，大多数患者为多关节型PsA（87.1%）。总体而言，142例患者在ETN治疗6个月后达到缓解。在第6个月处于缓解状态且持续参与研究直至结束的83例患者中，72例（86.7%）在第66个月时仍处于缓解状态。6个月后，66例患者接受ETN单药治疗，大多数患者持续接受该治疗直至第66个月（n = 22/26；84.6%）。
在该患者群体中，缓解状态实现迅速且能长期维持。在接受单药治疗的患者中，大多数在研究期间持续采用该治疗策略。
